|
⚲
|
| Keyboard |
| VR Adviser LLC
✚
|
|
|---|---|
| CRD # | 169288 |
| SEC # | 801-79382 |
| CIK # | 0001615982 |
| AUM | 4,495.4 M (2026-04-28) |
| Employees | 11 (100% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 212-444-4100 |
| Address | 7 Bryant Park New York, NY 10018 |
| Source | [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn] [Facebook] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (4/28/2026) [Brochure] |
|---|
Item 5 - Fees and Compensation
A. The Funds are “qualified purchasers” as defined in the Investment Company Act (and interests in the
Funds are only offered to qualified purchasers). Investors and prospective investors should refer to
the Funds’ governing and offering documents for a detailed description of the fees associated with
investments in the Funds.
B. The Firm deducts management fees (the “Management Fee”) directly from the Funds’ assets,
quarterly in advance. The Firm is also entitled to a performance fee (the “Carried Interest
Distributions”), based on cumulative net profits from investments. Carried Interest Distributions, if
applicable, are deducted directly from Funds’ assets under circumstances specified in each Fund’s
governing and offering documents.
C. The Funds will pay all expenses (other than routine general and administrative expenses, such as staff
salaries, office rent, and overhead) attributable to the ordinary and extraordinary expenses and
activities of each Fund, to the extent not paid or reimbursed by a portfolio company, including but
not limited to: (a) all expenses incurred in connection with the selection, purchase, holding,
monitoring, sale or exchange (including registration or regulatory filings by the Funds or the General
Partners) of securities, including, but not limited to, all custody, accounting, administration, research
and research related expenses (such as expenses of third-party expert networks and research
databases), transfer fees, brokerage commissions, buy-side and sell-side investment banking or
underwriting fees and interest expense, and expenses of third party consultants assisting in
investment due diligence); (b) the cost of liability insurance (including cybersecurity liability); (c) all
legal, regulatory (including anti-money laundering), accounting, auditing, bookkeeping, fund
administration, valuation and tax services (including preparing, reviewing and filing tax returns, tax
estimates, Schedules K-1 or other similar forms and related communications with partners) and
software (including developing, licensing and implementing any investor portal, computer software
or other administrative, valuation or reporting tools or services); (d) all expenses associated with the
preparation of the Funds’ financial statements and reports; (e) expenses of Fund transactions that are
not consummated; (f) expenses of the Limited Partner Advisory Committee, and all out-of-pocket
costs associated with meetings of the partners or Limited Partner Advisory Committee; (g) taxes, and
fees and expenses relating to tax structuring of the Funds’ and Fund investments; (h) financing,
origination, loan administration and similar fees incurred by the Funds and any interest on money
borrowed by the Funds; (i) expenses incurred in connection with the formation, organization and
syndication of the Funds and the General Partners (including travel expenses associated with
Venrock Adviser, LLC Form ADV Part 2A 2026
Brochure
marketing of Fund interests); (j) expenses attributable to the dissolution and windup of the Funds; (k)
expenses related to (i) the registration of VRA with the SEC, (ii) the maintenance of such registration
(including expenses related to the preparation, amendment and filing of Form ADV and Form PF), and
(ii) the compliance by VRA with the general regulatory and compliance obligations imposed on
investment advisers (including expenses related to any audit, examination or request by the SEC); (l)
legal and consulting fees associated with the obligations described in foregoing clause (k); (m) all fees
and expenses incurred in prosecuting, defending or settling administrative or legal proceedings
relating to the Funds brought by or against the Funds, the General Partners, their affiliates, or any of
their respective current or former members, partners, employees or agents, including indemnity
obligations and expenses that are not normal operating expenses; and (n) expenses incurred by the
General Partners or their affiliates in serving as partnership representative..
Clients are generally required to pay Management Fees quarterly in advance, as specified in each
Fund’s governing and offering documents. In the event VRA or its affiliates do not provide services
for the full quarterly period, the Management Fee is typically prorated for the partial period. In
general, the proration of fees is calculated based on the number of days remaining in the applicable
period.
D. Neither VRA nor any of its supervised persons anticipate receiving, directly or indirectly, any
compensation from the sale of securities or other investment products. |
| Account Minimums and Types of Clients — Form ADV Part 2A (4/28/2026) [Brochure] |
|---|
Item 7 - Types of Clients VRA provides investment advice to the Funds, which are private investment vehicles that are exempt from registration under the Investment Company Act. The Funds’ investors are limited to individuals and entities that meet certain suitability criteria including “accredited investors”, “qualified clients” and “qualified purchasers.” The Funds are marketed exclusively to institutional investors and high net worth individuals that meet these criteria. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Apogee Therapeutics Inc | 0.7 | ||
| Erasca Inc | 0.3 | ||
| ARCA Biopharma Inc | 0.2 | ||
| Aeglea Biotherapeutics Inc | 0.2 | ||
| Magenta Therapeutics Inc | 0.1 | ||
| Galecto Inc | 0.1 | ||
| Ocular Therapeutix Inc | 0.1 | ||
| UNUM Therapeutics Inc | 0.1 | ||
| Signal Genetics Inc | 0.1 | ||
| Adventrx Pharmaceuticals Inc | 0.1 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Venrock Healthcare Capital Partners XP LP | [2025-02-25] | 500.0 M | 493.0 M |
| Offered $500,000,000 · Filed 2024-11-20 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Venrock Opportunities Fund LP | [2022-03-25] | 675.0 M | 679.9 M |
| Offered $675,000,000 · Filed 2021-04-23 (D) · Exemption 506(b), 3(c)(7) · Duration One year or less · Revenue Not Applicable | ||||
| HF | Venrock Healthcare Capital Partners EG LP | [2021-03-30] | 446.8 M | 2,404.0 M |
| Offered $446,750,000 · Filed 2020-04-22 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Venrock Healthcare Capital Partners III LP | [2019-03-26] | 400.0 M | 761.5 M |
| Offered $400,000,000 · Filed 2018-04-20 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | VHCP Co-Investment Holdings III LLC | 2019-03-26 | 75.8 M | |
| PE | Venrock Healthcare Capital Partners II LP | [2014-07-31] | 59.5 M | |
| Offered $200,000,000 · Filed 2014-03-11 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $200,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Venrock Healthcare Capital Partners LP | [2014-07-31] | 1.4 M | |
| PE | VHCP Co-Investment Holdings II LLC | 2014-07-31 | 21.7 M | |
| PE | VHCP Co-Investment Holdings LLC | 2014-07-31 | 0.3 M | |
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 7 | 4.5 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 7 | 4.5 |
| By Discretionary | ||
| Discretionary | 7 | 4.5 |
| Non-Discretionary | 0 | 0.0 |
| Total | 7 | 4.5 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 4.5 | |
| Total | 7 | 4.5 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Anders Hove | Director | 16 | 4 | |
| Bong Koh | Director | 13 | 3 | |
| Nimish Shah | Director | 9 | 2 | |
| VR Management LLC | Promoter | 5 | 2 | |
| VR Adviser LLC | Promoter | 2 | 1 | |
| Vhcp Management II LLC | Director | 1 | 1 | |
| Venrock Opportunities Management LLC | Director | 1 | 1 | |
| Bryan E Roberts | Director | 1 | 1 | |
| Vhcp Management XP LLC | Director | 1 | 1 | |
| Vhcp Management Eg LLC | Director | 1 | 1 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001615982] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.5B |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| Comparable Firms | State | AUM |
|---|---|---|
|
Washington Harbour Partners LP
✚
|
VA | 4,725.1 M |
|
Redmile Group LLC
✚
|
CA | 4,701.1 M |
|
Clearwater Management Co Inc
✚
|
MN | 4,681.9 M |
|
Shelter Growth Capital Partners LLC
✚
|
CT | 4,662.5 M |
|
Caxton Associates USA LLC
✚
|
NY | 4,627.3 M |
|
Corvex Management LP
✚
|
NY | 4,568.4 M |
|
Evanston Capital Management LLC
✚
|
IL | 4,490.6 M |
|
Luminarx Capital Management LP
✚
|
NY | 4,460.7 M |
|
Skyknight Capital LP
✚
|
CA | 4,428.5 M |
|
LGK Advisors LLC
✚
|
NY | 4,391.7 M |